- Home
- ORIC vs RCKT Comparison
ORIC vs RCKT Comparison
Compare ORIC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- RCKT
- Stock Information
- Founded
- ORIC 2014
- RCKT 1999
- Country
- ORIC United States
- RCKT United States
- Employees
- ORIC N/A
- RCKT N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- RCKT Health Care
- Exchange
- ORIC Nasdaq
- RCKT Nasdaq
- Market Cap
- ORIC 362.9M
- RCKT 326.4M
- IPO Year
- ORIC 2020
- RCKT N/A
- Fundamental
- Price
- ORIC $9.35
- RCKT $2.70
- Analyst Decision
- ORIC Strong Buy
- RCKT Buy
- Analyst Count
- ORIC 8
- RCKT 13
- Target Price
- ORIC $18.83
- RCKT $18.50
- AVG Volume (30 Days)
- ORIC 2.0M
- RCKT 8.1M
- Earning Date
- ORIC 08-11-2025
- RCKT 08-04-2025
- Dividend Yield
- ORIC N/A
- RCKT N/A
- EPS Growth
- ORIC N/A
- RCKT N/A
- EPS
- ORIC N/A
- RCKT N/A
- Revenue
- ORIC N/A
- RCKT N/A
- Revenue This Year
- ORIC N/A
- RCKT N/A
- Revenue Next Year
- ORIC N/A
- RCKT N/A
- P/E Ratio
- ORIC N/A
- RCKT N/A
- Revenue Growth
- ORIC N/A
- RCKT N/A
- 52 Week Low
- ORIC $3.90
- RCKT $2.19
- 52 Week High
- ORIC $14.67
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- ORIC 62.84
- RCKT 32.09
- Support Level
- ORIC $8.85
- RCKT $2.66
- Resistance Level
- ORIC $9.54
- RCKT $3.33
- Average True Range (ATR)
- ORIC 0.74
- RCKT 0.28
- MACD
- ORIC -0.07
- RCKT 0.09
- Stochastic Oscillator
- ORIC 50.98
- RCKT 26.59
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.